This was published yesterday and it is from The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Australia. I could not get the paper itself but here is the abstract. I would say that Masters, for sure, knows this info and would not go to a new study with PBT2 if this were the case with PBT2. But I do not know what did happen with PBT2. Looks like secretase inhibitors and monoclonal antibodies are the worst.doi: 10.1212/WNL.0000000000207156. Online ahead of print.Accelerated Brain Volume Loss Caused by Anti-β-Amyloid Drugs: A Systematic Review and Meta-analysis
AffiliationsDOI: 10.1212/WNL.0000000000207156
- PMID: 36973044
Abstract
Objectives: To evaluate brain volume changes caused by different sub-classes of anti-amyloid beta (Aβ) drugs trialled in patients with Alzheimer's disease.
Methods: PubMed, Embase and Clinicaltrial.gov databases were searched for clinical trials of anti-Aβ drugs. This systematic review and meta-analysis included adults enrolled in randomized controlled trials of anti-Aβ drugs (n=8062 to 10279). The inclusion criteria were as follows: (1) randomized controlled trials of patients treated with anti-Aβ drugs that have demonstrated to favourably change at least one biomarker of pathological Aβ; and (2) detailed MRI data sufficient to assess the volumetric changes in at least one brain region. MRI brain volumes were used as the primary outcome measure; brain regions commonly reported include the hippocampus, lateral ventricle and whole brain. Amyloid-Related Imaging Abnormalities (ARIA) were investigated when reported in clinical trials. Of the 145 trials reviewed, 31 were included in the final analyses.
Results: A meta-analysis on the highest dose of each trial on hippocampus, ventricle, and whole brain revealed drug-induced acceleration of volume changes that varied by anti-Aβ drug class. Secretase inhibitors accelerated atrophy to the hippocampus (mean difference: -37.1 µL [-19.6% relative to change in placebo]; 95% confidence interval: -47.0 to -27.1) and whole brain (-3.3mL [-21.8% relative to change in placebo]; 95% confidence interval: -4.1 to 2.5). Conversely, ARIA-inducing monoclonal antibodies accelerated ventricular enlargement (mean difference: +2.1mL [+38.7% relative to change in placebo]; 95% confidence interval: 1.5 to 2.8) where a striking correlation between ventricular volume and ARIA frequency was observed (r=0.86, p=6.22x10-7). Mild Cognitively Impaired participants treated with anti-Aβ drugs were projected to have a material regression toward brain volumes typical of Alzheimer's dementia ∼8 months earlier than if they were untreated.
Conclusions: These findings reveal the potential for anti-Aβ therapies to compromise long-term brain health by accelerating brain atrophy, and provide new insight into the adverse impact of ARIA. Six recommendations emerge from these findings.
- Forums
- ASX - By Stock
- ATH
- Brain Volume Loss Caused by Anti-β-Amyloid Drugs
ATH
alterity therapeutics limited
Add to My Watchlist
0.00%
!
0.8¢

Brain Volume Loss Caused by Anti-β-Amyloid Drugs
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $53.25M |
Open | High | Low | Value | Volume |
0.8¢ | 0.8¢ | 0.8¢ | $36.27K | 4.534M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 12435327 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 966667 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
22 | 12435327 | 0.007 |
10 | 9160008 | 0.006 |
11 | 7600001 | 0.005 |
9 | 12120001 | 0.004 |
9 | 11933333 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 966667 | 2 |
0.009 | 5961100 | 12 |
0.010 | 14622823 | 23 |
0.011 | 10843306 | 11 |
0.012 | 6882727 | 10 |
Last trade - 16.10pm 02/04/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |